Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth

Kimiyasu Egami, Toyoaki Murohara, Toshifumi Shimada, Ken-ichiro Sasaki, Satoshi Shintani, Takeshi Sugaya, Masahiro Ishii, Teiji Akagi, Hisao Ikeda, Toyojiro Matsuishi, and Tsutomu Imaizumi

Although the renin-angiotensin system (RAS) is a major regulator of vascular homeostasis, the role of the RAS in tumor angiogenesis is little understood. Here we show that host angiotensin II (ATII) type 1 (AT1) receptor plays an important role in angiogenesis and growth of tumor cells engrafted in mice. Subcutaneous B16-F1 melanoma-induced angiogenesis as assessed by tissue capillary density and microangiography was prominent in WT mice but was reduced in AT1a receptor–deficient (AT1a+/−) mice. Consequently, tumor growth rate was significantly slower, and the mouse survival rate was greater, in AT1a−/− mice than in WT mice. Tumor growth was also reduced in WT mice treated with TCV-116, a selective blocker of AT1 receptor. Because the β-galactosidase gene was inserted into the AT1a gene locus in AT1a+/− mice, the site of β-galactosidase expression represents the AT1a receptor expression in these mutant mice. In tumor-implanted AT1a−/− mice, the major site of the β-galactosidase expression was macrophages in tissues surrounding tumors. Moreover, the number of infiltrated macrophages was significantly lower in AT1a+/− mice than in WT mice, and double-immunofluorescence staining revealed that these macrophages expressed VEGF protein intensively. Therefore, the host ATII-AT1 receptor pathway supports tumor-associated macrophage infiltration, which results in enhanced tissue VEGF protein levels. The host ATII-AT1 receptor pathway thereby plays important roles in tumor-related angiogenesis and growth in vivo.


Introduction

The renin-angiotensin system (RAS) plays important roles in the regulation of vascular homeostasis (1). A recent large-scale clinical trial for hypertension demonstrated that angiotensin-converting enzyme (ACE) inhibitors reduced not only the mortality rate due to cardiovascular diseases but also the rate due to malignant tumors (2). Because tumor growth depends on angiogenesis (3, 4), one may speculate that ACE inhibitors might have reduced tumor angiogenesis and growth. In fact, an ACE inhibitor, captopril, has been shown to inhibit tumor angiogenesis (5). In other experimental models, however, for example in a reparative hindlimb ischemia model (6, 7), ACE inhibitors augmented angiogenesis, leaving the role of the RAS in angiogenesis unclear.

In many previous studies, ACE inhibitors were mainly used to suppress the functions of the RAS as a pharmacological tool; however, ACE inhibitors suppress not only the synthesis of angiotensin II (ATII) but also the activity of kininase II (8). Consequently, ACE inhibitors increase tissue bradykinin concentration, which stimulates endothelial NO release and thereby affects angiogenesis (8, 9). Moreover, ATII is synthesized by another enzyme, chymase (10). Therefore, the use of ACE inhibitors alone cannot fully elucidate the precise role of ATII in angiogenesis in vivo.

To further elucidate the role of ATII in tumor-related angiogenesis, we sought to determine the effects of the blockade of functional ATII receptor on angiogenesis in vivo. There are two major subtypes of ATII receptors, AT type 1 and 2 (AT1 and AT2) (11). The AT1 receptor is further subdivided into AT1a and AT1b in murine species. Most of the ATII functions in the cardiovascular system are mediated through the AT1 receptor, and inhibitors might have reduced tumor angiogenesis and growth. Although the renin angiotensin system (RAS) is a major regulator of vascular homeostasis, the role of the RAS in tumor angiogenesis is little understood. Here we show that host angiotensin II (ATII) type 1 (AT1) receptor plays an important role in angiogenesis and growth of tumor cells engrafted in mice. Subcutaneous B16-F1 melanoma-induced angiogenesis as assessed by tissue capillary density and microangiography was prominent in WT mice but was reduced in AT1a receptor–deficient (AT1a+/−) mice. Consequently, tumor growth rate was significantly slower, and the mouse survival rate was greater, in AT1a−/− mice than in WT mice. Tumor growth was also reduced in WT mice treated with TCV-116, a selective blocker of AT1 receptor. Because the β-galactosidase gene was inserted into the AT1a gene locus in AT1a+/− mice, the site of β-galactosidase expression represents the AT1a receptor expression in these mutant mice. In tumor-implanted AT1a−/− mice, the major site of the β-galactosidase expression was macrophages in tissues surrounding tumors. Moreover, the number of infiltrated macrophages was significantly lower in AT1a+/− mice than in WT mice, and double-immunofluorescence staining revealed that these macrophages expressed VEGF protein intensively. Therefore, the host ATII-AT1 receptor pathway supports tumor-associated macrophage infiltration, which results in enhanced tissue VEGF protein levels. The host ATII-AT1 receptor pathway thereby plays important roles in tumor-related angiogenesis and growth in vivo.
in rodents they are mediated through the AT1a receptor (11–14). We took advantage of employing genetically modified AT1a receptor-deficient (AT1a–/–) mice, which we generated previously (15), and examined the role of the ATII-AT1a receptor system in host animals in tumor growth and angiogenesis in vivo. We also examined the effects of a selective AT1 receptor antagonist TCV-116 on tumor angiogenesis and growth in WT animals (12).

Methods
AT1a receptor–deficient mouse. To obtain AT1a receptor–deficient heterozygous (AT1a+/–) mice, a germline chimera derived from TT2 ES cells with a targeted mutation of the AT1a gene (15), was backcrossed for five generations with C57BL/6 mice (16). The resulting AT1a+/– F3 mice were intercrossed to generate the homozygous (AT1a–/–) mutant mice. In the AT1a–/– mice the AT1a gene was deleted, and the β-galactosidase gene was inserted into its original gene locus. Consequently, AT1a receptor expression can be analyzed by the β-galactosidase gene or protein expression in AT1a–/– mice (15, 16). As WT (or AT1a+/–) control mice, C57BL/6 mice were obtained from CLEA Japan Inc. (Tokyo, Japan). Male mice, 8–10 weeks old, were used.

Tumor implantation model. Study protocols were approved by the Institutional Animal Care and Use Committee of Kurume University School of Medicine. We used a mouse model of tumor angiogenesis as described previously (17). We employed two different cell lines, B16-F1 melanoma and QRSp-11 fibrosarcoma cells, which can grow in the C57BL/6 strain mouse (17, 18). B16-F1 melanoma cells (batch no. 1224725, flask passage no. 26) were purchased from the American Type Culture Collection (Manassas, Virginia, USA). Cells were cultured in DMEM supplemented with 4 mM l-glutamine, 4.5 g/l glucose, 10% FBS, and antibiotics (Life Technologies Inc., Gaithersburg, Maryland, USA) under humidified air with 5% CO2 at 37°C. Before use, the melanoma cell monolayer in culture was washed and detached with PBS containing 0.25% trypsin and 0.03% EDTA and then pelleted by brief centrifugation at 100 g. The supernatant was removed, cell pellets were resuspended in PBS, and the cell number was counted (Sysmex Inc., Tokyo, Japan). The cell concentration was finally adjusted to 5 × 10⁶ cells/ml, and 200 µl of the suspension was injected subcutaneously into WT mice (n = 11) and AT1a+/– mice (n = 12) in the dorsal skin using a disposable tuberculin syringe and a 27-gauge needle under anesthesia (30 mg/kg pentobarbital, intraperitoneally). QRSp-11 fibrosarcoma cells were kindly provided by F. Okada at Hokkaido University, Sapporo, Japan. Cells were cultured in MEM supplemented with 110 mg/l sodium pyruvate, nonessential amino acids, l-glutamine (292.3 mg/l), 10% FBS, and antibiotics under humidified air with 5% CO2 at 37°C. Cells were otherwise identically isolated from culture dishes, as were B16-F1 melanoma cells. The cell concentration was finally adjusted to 2 × 10⁶ cells/ml, and 200 µl of the suspension was injected subcutaneously into WT mice (n = 22) and AT1a–/– mice (n = 15) in the dorsal skin.

At several time points after tumor implantation, the size of tumor was measured using a caliper. The tumor volume was calculated according to the formula (V = [L × W²] × 0.52), where V = volume, L = length, and W = width (length is greater than width) (19). Before cell implantation, systemic arterial blood pressure and heart rate were measured in the conscious state using a small animal tail-cuff BP analyzer (MK2000; Muro-machi Kikai Co. Ltd., Tokyo, Japan).

Microangiography. Postmortem tumor microangiography was performed on day 21 after melanoma cell implantation in both WT and AT1a–/– mice (n = 4 in each group). Under deep anesthesia with pentobarbital sodium (60 mg/kg, intraperitoneally), the thoracic cavity was rapidly opened, and a 24-gauge soft-tip catheter was inserted through the apex into the left ventricular cavity. The aorta was gently perfused with 1 ml of warm saline (37°C) containing heparin (10 U/ml), which was followed by injection of filtered barium sulfate (0.25 g/ml, 0.3 ml; Fushimi Corp., Kagawa, Japan). The whole bodies of the mice were immediately fixed with 20% formalin solution overnight, and a portion of primary tumor and adjacent subcutaneous tissues surrounding the tumors was isolated as a tissue block. Multiple tissue slices 1 mm thick were prepared by using a microtome through their center, taking surrounding tissue. The slices from each tumor were subjected to microangiography using an x-ray mummography system (Senographe 500T; GE Medical Systems- Europe, Paris, France) (20).

Capillary-density analysis. On day 21 after melanoma implantation, tumors and subcutaneous tissues surrounding tumors (approximately 3 mm from the tumor margin) were carefully isolated, fixed in methanol overnight, and embedded in paraffin. Multiple tissue slices 5 µm thick were prepared from both WT and AT1a+/– mice (n = 6 in each group). Endothelial cells were immunohistochemically stained to examine the capillary density. In brief, capillary endothelia was identified by staining with either a rat anti-mouse CD31 mAb (PharMingen, San Diego, California, USA) or a rat anti-human vWF mAb (DAKO A/S, Glostrup, Denmark), followed by immunoperoxidase staining using a commercially available kit (VectaStain ABC-PO; Vector Laboratories, Burlingame, California, USA). The rat anti-human vWF mAb cross-reacts with mouse endothelial cells. Final color products were developed using a solution containing 3, 3′-diaminobenzidine (DAB) and NiCl₂ (DAB substrate kit; Vector Laboratories).

For the analysis of the capillary density in skeletal muscles on day 21, tissues located just below tumors were isolated and snap-frozen in OCT compound with liquid N₂. Five-micrometer-thick frozen sections were prepared from each specimen so that the muscle fibers were oriented in a transverse fashion. The sections were stained for alkaline phosphatase to detect capillary...
endothelial cells within skeletal muscle tissues as described previously (21). Fifteen random microscopic fields from three different sections in each tissue were examined for the presence of capillary endothelial cells under light microscopy, and capillary density was expressed as the number of capillaries per high-power field (×400). The final capillary-density score represents an average of all fields.

**Histological analysis of tumor-associated macrophage infiltration.** Macrophages express AT1a receptors (22), and AT III has been shown to evoke inflammatory responses in various tissues (16, 23). Moreover, macrophage infiltration is an important promoter for tumor angiogenesis and growth (24–27), and these cells are called tumor-associated macrophages (TAMs). We thus examined TAM infiltration around melanoma tissues and compared the number of infiltrated TAMs between WT and AT1a−/− mice. Leukocyte infiltration was first analyzed by a standard H&E staining method in multiple sections prepared from paraffin-embedded tissues. Cryostat sections 5 μm thick from tumors and surrounding subcutaneous tissues were then mounted on silicone-coated slides, and TAMs were immunohistochemically identified using a rat anti-mouse macrophage mAb (clone F4/80; Serotec Ltd., Oxford, United Kingdom) followed by an immunoperoxidase staining using the VectaStain ABC-PO kit and DAB substrate (Vector Laboratories). TAMs were defined as infiltrated macrophages located around tumors and within a distance of 3,000 μm from the tumor margin.

**Histological analysis of VEGF expression.** Infiltrated macrophages release angiogenic cytokines, including VEGF, which promote angiogenesis (23). We thus examined VEGF protein expression in TAMs by a double-immunofluorescence staining. Cryostat sections 5 μm thick from tumors and surrounding subcutaneous tissues were mounted on silicone-coated slides. They were incubated overnight at 4°C with an anti–mouse VEGF mAb (HyTest Ltd., Turku, Finland) and with an anti-mouse macrophage mAb (F4/80) in a moist chamber. The slides were then further incubated for 30 minutes at 37°C with a PE-conjugated anti-rat IgG (Serotec Ltd., Turku, Finland) to detect macrophages. The slides were examined under fluorescence microscopy (DIAPHOT 300; Nikon Corp.).

**Measurement of tissue monocyte chemoattractant protein–1 and VEGF levels.** Because infiltration of macrophages is associated with expression of chemokine MCP-1, we determined tissue levels of monocyte chemoattractant protein–1 (MCP-1) protein using ELISA. Subcutaneous tissues surrounding tumors 3 mm thick were isolated from the surface of tumors, and tissues were homogenized and centrifuged for 15 minutes at 3,500 g at 4°C. Supernatant was then recovered, and MCP-1 levels were determined using a mouse MCP-1 ELISA kit (Quantikine M; R&D Systems Inc., Minneapolis, Minnesota, USA). Because infiltrated macrophages release an angiogenic cytokine VEGF, we also determined the tissue VEGF levels using a mouse VEGF ELISA kit (Quantikine M; R&D Systems Inc.). Finally, VEGF protein levels within tumor masses without necrosis were also determined using the ELISA method. Data are expressed as picograms per milligram of tissue.

**Effects of an angiogenesis inhibitor O-(chloroacetyl-carbamoyl)umagillicol on tumor angiogenesis and growth in WT and AT1a−/− mice.** We examined whether angiogenesis inhibitor O-(chloroacetyl-carbamoyl)umagillicol (TNP-470) (28, 29), could inhibit melanoma growth and angiogenesis in vivo. TNP-470 treatment was initiated on the day of tumor implantation, and mice received TNP-470...
(30 mg/kg, subcutaneously) every other day. This treatment regimen and the dose of TNP-470 have been shown to effectively block angiogenic response in murine experimental models (29).

Effects of a selective AT1 receptor blocker TCV-116 on tumor angiogenesis and growth in WT mice. We evaluated whether pharmacological blockade of the AT1 receptor function by treatment with TCV-116, a potent and selective AT1 receptor blocker (12, 30, 31), could inhibit melanoma growth and angiogenesis in WT mice in vivo. Some mice received TCV-116 treatment (10 mg/kg/day, orally) initiated 7 days prior to tumor implantation, and the tumor growth was compared between TCV-116–treated (n = 17) mice and untreated WT mice (n = 16).

Statistics. All values are presented as mean plus or minus SE. Data were subjected to paired or unpaired Student t tests for comparison between WT and AT1a−/− mice. When comparing more than three groups, ANOVA with post hoc analysis was used. The rate of mouse survival was compared between the tumor-implanted WT and AT1a−/− groups by the Kaplan-Meier method (32). P values of less than 0.05 were considered to be statistically significant.

Results

Tumor growth in WT mice and the effects of TNP-470. First, to evaluate whether subcutaneous melanoma growth depends on angiogenesis, B16-F1 melanoma cells (10^6/animal) were implanted into the dorsal skin tissues of either WT mice or AT1a−/− mice, and we examined the effects of TNP-470, a potent angiogenesis inhibitor, on tumor growth. The growth of engrafted tumors was significantly inhibited in both WT mice and AT1a−/− mice receiving TNP-470 compared with control WT and AT1a−/− mice (Figure 1, a and b). The inhibitory efficacy of TNP-470 on tumor growth was more prominent in WT mice compared with AT1a−/− mice. Postmortem tumor microangiography on day 21 revealed that the formation of visible tumor-associated vessels visible with microangiography was less potent in tumors engrafted in mice receiving TNP-470 in both WT mice and AT1a−/− mice, compared with those engrafted in mice receiving saline (Figure 1c). These data suggest that subcutaneous melanoma growth is indeed dependent on angiogenesis.

Tumor growth and mouse survival in WT and AT1a−/− mice. B16-F1 melanoma cells (10^6 cells/animal) were implanted into the dorsal skin of WT and AT1a−/− mice. The two groups of mice exhibited similar tumor engraftment rates during the first 7 days after implantation; however, tumors engrafted in AT1a−/− mice continued to grow more slowly than did tumors in WT mice. By postimplantation day 21, the mean size of tumors grafted in AT1a−/− mice was significantly smaller than that in WT mice (Figure 2a). The Kaplan-Meier analysis showed that the rate of host mouse survival was significantly higher in the AT1a−/− group than in the WT group (Figure 2b), consistent with the data of tumor growth. These data suggest an important role of the host AT1a receptor in supporting tumor growth.
ing tumors was also lower in AT1α−/− mice (30 ± 2/field) than in WT mice (52 ± 8/field) (Figure 3, e, f, and j).

Likewise, the density of alkaline phosphatase–positive capillary endothelial cells within skeletal muscles underlying tumors was significantly lower in AT1α−/− mice (26 ± 5/field) than in WT mice (38 ± 5/field) (Figure 3, g, h, and k). Overall, we found that the tumor-associated capillary-density score was significantly lower in tissues obtained from AT1α−/− mice compared with those obtained from WT mice.

AT1α receptor expression. We examined tissue AT1α receptor expression. First, RT-PCR analysis in isolated

X-ray microangiography. We performed postmortem tumor microangiography on day 21 after B16-F1 melanoma cell implantation. We found that the formation of tumor-feeding vessels visible with angiography was less potent in tumors engrafted in AT1α−/− mice compared with those engrafted in WT mice (Figure 3, a and b).

Capillary density. We evaluated the capillary density by immunohistochemistry, since this is a measure of tumor-associated capillary angiogenesis. The density of CD31-positive capillary vessels inside tumors was significantly lower in AT1α−/− mice (18 ± 3/field) than in WT mice (37 ± 4/field) (Figure 3, c, d, and i). The density of vWF-positive vessels in subcutaneous tissue surround-

**Figure 3**

Decreased vascular density in and around B16-F1 melanomas implanted in AT1α−/− mice. Serial photo panels indicate representative x-ray microangiograms of melanomas grown in WT (a) or AT1α−/− (b) mice, CD31-stained melanoma mass grown in WT (c) or AT1α−/− mice (d) (×200), vWF-stained subcutaneous tissues surrounding B16-F1 melanomas grown in WT (e) or AT1α−/− mice (f) (×200), and alkaline phosphatase-stained skeletal muscle tissues underlying B16-F1 melanomas grown in WT (g) or AT1α−/− mice (h) (×400). Bars indicate 50 µm. The capillary densities of (i) tumors, (j) subcutaneous tissue surrounding tumors, and (k) skeletal muscles underlying tumors were all significantly smaller in AT1α−/− mice (n = 6) than in WT mice (n = 6). Values represent the average number of vessels at ×200 ± the SE (by Student t test).
tissues revealed that cultured B16-F1 melanoma cells themselves expressed AT1a receptor mRNA. In tumor-engrafted WT mice, AT1a receptor mRNA was expressed in tumors and subcutaneous tissues surrounding tumors (Figure 4a). On the other hand, in tumor-engrafted AT1a−/− mice, AT1a receptor mRNA was expressed only in tumor tissues that derived from implanted B16-F1 melanoma cells themselves. We found trace expression of AT1a receptor mRNA in subcutaneous tissues surrounding tumors, which presumably derived from B16-F1 melanoma cells invading from implanted tumors (Figure 4a). We then examined β-galactosidase mRNA expression by RT-PCR in tissues obtained from AT1a−/− mice, because the AT1a receptor gene was deleted and the β-galactosidase gene was inserted into the AT1a receptor gene locus (15). RT-PCR analysis revealed that β-galactosidase mRNA was expressed predominantly in subcutaneous tissues overlying tumors and was little expressed in tumors (Figure 4b). The intensity of the β-galactosidase mRNA expression was greater in subcutaneous tissues overlying tumors than in normal subcutaneous tissues. Accordingly, the host AT1a receptor expression as determined by β-galactosidase expression was enhanced in tissues surrounding tumors but not in normal subcutaneous tissues in AT1a−/− mice.

**Tissue inflammatory responses.** From the results above, we see that the host AT1a receptor is mainly expressed in tissues surrounding tumors. Recent studies indicated that the RAS plays important proinflammatory roles in various disease models (16, 23, 33, 34), and inflammation is an important trigger for angiogenesis (26, 35). We therefore examined inflammatory responses around tumor tissues isolated on postimplantation day 21. Standard H&E staining revealed an infiltration of inflammatory leukocytes in WT mice (Figure 4c). We then stained tissue sections using the F4/80 mAb to detect macrophages, because TAMs are important triggers for tumor angiogenesis. The quantitative analysis revealed that the number of infiltrated F4/80-positive TAMs was significantly lower in AT1a−/− mice than in WT mice (Figure 4c). Interestingly, immunohistochemical examination using anti-β-galactosidase mAb revealed that the major site of the expression of AT1a receptor was TAMs (Figure 4c).

**Macrophages express angiogenic cytokine VEGF.** TAMs release various angiogenic cytokines, including VEGF, that promote tumor neovascularization (24–27). To further examine the relationship between infiltrated TAMs and VEGF expression in tissues, we performed double-immunofluorescence staining for VEGF and the macrophage marker, F4/80. VEGF and F4/80 double-positive macrophages were predominantly located in subcutaneous tissues surrounding tumors (Figure 5a). The number of infiltrated VEGF-positive TAMs was less in AT1a−/− mice than in WT mice (Figure 5b). ELISA of tissue homogenates revealed that tissue levels of VEGF and MCP-1 proteins were significantly lower in AT1a−/− mice than in WT mice (Figure 5b); however, the levels of VEGF protein in homogenized tumor masses standardized with total protein concentration were not significantly different between the two groups (21 ± 1.9 in WT versus 24 ± 1.3 pg/mg protein).

**Figure 4**
Host AT1a receptor is expressed on tumor-associated macrophages. (a) RT-PCR analysis for AT1a mRNA shows cultured B16-F1 melanoma cells, and implanted tumor tissues express AT1a mRNA. Subcutaneous tissues surrounding tumors expressed AT1a mRNA in WT mice but only slightly in AT1a−/− mice. (b) RT-PCR analysis for β-galactosidase (β-gal) mRNA in AT1a−/− mice shows subcutaneous tissues surrounding tumors express β-galactosidase (equivalent expression site of host AT1a receptor). β-Galactosidase mRNA is little expressed in tumors, indicating the absence of the host AT1a receptor within tumor tissues. (c) Subcutaneous tissues isolated from a remote normal skin and tumor-implanted site were stained with an FITC-conjugated anti-β-galactosidase mAb (representing host AT1a receptor) (FITC-β-gal) and phycoerythrin-conjugated anti-macrophage mAb (PE-macrophage). Panels indicate that macrophages located around tumors (TAMs) express β-galactosidase (host AT1a receptor). Bars indicate 100 µm. T, tumor.
Effects of TCV-116 on melanoma angiogenesis and growth. Because subcutaneous melanoma-induced angiogenesis and growth were reduced in AT1a–/– mice, we evaluated the effects of a selective AT1 receptor blocker on tumor angiogenesis in WT mice in vivo. Treatment with TCV-116, a selective AT1 receptor blocker, inhibited melanoma growth and angiogenesis assessed by microangiography (Figure 6, a and b). Thus, pharmacological blockade with AT1 receptor also inhibits melanoma-induced angiogenesis and growth, which mimicked tumor growth suppression observed in AT1a–/– mice.

Discussion
Although the RAS is an important system in regulating vascular homeostasis, the precise roles of the RAS and the ATII-AT1 receptor pathway in angiogenesis, especially in tumor-related angiogenesis, are unclear. To elucidate this issue, we took advantage of using genetically modified AT1a–/– mice that we had generated recently (15, 16). In the present study, we demonstrate, for the first time, that the host ATII-AT1 receptor pathway plays an important role in tumor-related angiogenesis and growth. Moreover, these phenomena in AT1a–/– mice were at least in part mediated by reduced TAM infiltration, an important determinant of tumor angiogenesis.

Tumor growth requires the maintenance and expansion of a vascular network (3, 4). In fact, various angiogenesis inhibitors have been shown to suppress tumor growth and to induce tumor dormancy (28, 36, 37). In the present study, using two different tumor cell lines (B16-F1 melanoma and QRsP-11 fibrosarcoma cells), we found that in vivo tumor growth was significantly inhibited in AT1a–/– mice compared with WT mice. Consistently, the survival rate of host animals after tumor implantation was significantly greater in AT1a–/– mice than in WT mice. Among these two cell lines, we focused on B16-F1 melanoma cells because melanoma growth depends greatly on angiogenesis (20, 25–27). Moreover, infiltration of monocytes/macrophages is critical for progression of melanomas toward an aggressive phenotype (38), and macrophage infiltration correlates with the degree of angiogenesis and disease stage (27). Therefore, the present melanoma implantation model is a useful system to use to analyze tumor angiogenesis, tumor growth, tumor-related macrophage infiltration, and host survival simultaneously.

We found that B16-F1 melanoma growth and angiogenesis were significantly reduced in AT1a–/– mice. Moreover, in AT1a–/– mice, the inhibitory efficacy of
TNP-470 on tumor growth was less potent as compared with that in WT mice. The latter finding suggests that the AT1a receptor deficiency almost sufficiently inhibited tumor angiogenesis, which may have limited further antiangiogenic (antitumor growth) efficacy of TNP-470. There may be several possible explanations for the reduced tumor angiogenesis in AT1a−/− mice. Recent studies show that ATII acts as a proinflammatory molecule for immune-privileged tissues and cells (33, 34). In fact, macrophages express AT1 receptor intensively, and ATII enhances macrophage inflammatory functions through the AT1 receptor (22). Studies also suggest that infiltration of TAMs plays a pivotal role in tumor angiogenesis, enabling tumor cells to survive and proliferate (25), because macrophages can release various angiogenic growth factors, including VEGF, PDGF, IGF-1, bFGF, GM-CSF, IL-1, IL-6, IL-8, and TNF-α, which stimulate tumor growth. VEGF is one of the most prominent angiogenic cytokines among those factors and is released from infiltrated TAMs (23, 25). We reported recently that macrophage infiltration, VEGF release from macrophages, and angiogenesis were significantly reduced in AT1a−/− mice compared with WT mice in ischemic tissues (23). It is therefore conceivable that melanoma-associated macrophage infiltration and their cytokine release, especially VEGF, might be impaired, and thereby melanoma growth was retarded in AT1a−/− mice in the present study.

To further address these issues, we examined inflammatory response and VEGF protein expression in tumor-associated tissues. First, we found that the number of infiltrated macrophages was significantly lower in AT1a−/− mice than in WT mice in subcutaneous tissues surrounding tumors (approximately 3,000 µm from tumor margin). Second, infiltrated macrophages intensively expressed VEGF protein, and the level of VEGF protein was significantly lower in AT1a−/− mice than in WT mice in tissues surrounding tumors. Third, RT-PCR analysis revealed that host AT1a receptor expression (AT1a mRNA in WT mice and β-galactosidase mRNA in AT1a−/− mice) was located mainly in tissues surrounding tumors, and immunohistochemical analysis in AT1a−/− mice revealed that β-galactosidase protein was predominantly expressed on infiltrated TAMs. Thus, our findings suggest that the host AT1a receptor is preferentially expressed on TAMs, which release VEGF, and therefore the ATII-AT1a receptor pathway may play important roles in promoting tumor angiogenesis and growth in a TAM and VEGF-dependent manner. These are previously unknown important functions of the ATII-AT1 receptor pathway in tumor biology.

There are some limitations in the present study. First, we examined only two tumor types in one mouse strain (i.e., B16-F1 melanoma cells and QRSP-11 fibrosarcoma cells in C57BL/6 mice). Other tumor types combined with other experimental conditions should be analyzed. In this regard, two recent reports show that pharmacological blockade of AT1 receptor also reduced tumor angiogenesis, growth, and metastasis (39, 40), further supporting our findings. Second, the AT1 receptor is expressed on not only macrophages but also endothelial cells and VSMCs. Indeed, ATII has been shown to stimulate production of VEGF from VSMCs, and ATII directly enhances endothelial capillary network formation (41, 42). Thus, these mechanisms should also be involved in the reduced angiogenesis in AT1a−/− mice. Third, we used WT mice treated with a relatively high dose of TCV-116. Although the present regimen of TCV-116 administration does not elicit any cytotoxic actions in rodents (43, 44), our data may not be directly extrapolated to humans receiving clinical doses of TCV-116. We will need to analyze the dose-related effects of AT1 receptor blockers on tumor angiogenesis in vivo in the future. Finally, there is a possibility that melanoma itself releases VEGF protein that induces angiogenesis. Although the VEGF levels within tumor masses standardized with total protein were similar to each other between the two groups, the size of tumor mass was much smaller in AT1a−/− mice than in WT mice. Therefore, the overall release of VEGF protein from tumor mass could be still smaller in AT1a−/− mice than in WT mice.

In summary, our findings suggest that the host ATII-AT1 receptor pathway plays a significant role in tumor angiogenesis and growth in vivo. The mechanism is at least in part related to the ATII-mediated inflammatory TAM infiltration. These are newly discovered functions of the ATII-AT1 receptor pathway. Our study not only provides a novel insight into the pathogenesis of tumor angiogenesis, but also hints at a possible new therapeutic strategy against tumors.

Acknowledgments

This study was supported by Research Grants 12136208 and 14370235 and a Scientific Frontier grant from the Ministry of Education, Science and Culture, the Tokyo Biochemical Research Society, the Japan Heart Foundation, the Terumo Research Foundation, and grants from the Ministry of Health and Welfare (to T. Murohara). We thank K. Kimura, K. Moriyama, and M. Aoki for technical assistance, and Takeda Chemical Industries Inc. (Osaka, Japan) for TNP-116 and TNP-470.

References


